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Abstract: Cardiovascular disease is the leading cause of death worldwide. Within the 
treatment armamentarium, beta-blockers have demonstrated efﬁ  cacy across the spectrum 
of cardiovascular disease – from modiﬁ  cation of a risk factor (ie, hypertension) to treat-
ment after an acute event (ie, myocardial infarction). Recently, the use of beta-blockers as a 
ﬁ  rst-line therapy in hypertension has been called into question. Moreover, beta-blockers as 
a class are saddled with a misperception of having poor tolerability. However, vasodilatory 
beta-blockers such as carvedilol have a different hemodynamic action that provides the 
beneﬁ  ts of beta-blockade with the addition of vasodilation resulting from alpha 1-adrenergic 
receptor blockade. Vasodilation reduces total peripheral resistance, which may produce an 
overall positive effect on tolerability. Recently, a new, controlled-release carvedilol formu-
lation has been developed that provides the clinical efﬁ  cacy of carvedilol but is indicated 
for once-daily dosing. This review presents an overview of the clinical and pharmacologic 
carvedilol controlled-release data.
Keywords: beta-blockers, cardiovascular disease, heart failure, myocardial infarction, 
vasodilatory
Beta-blockers in the treatment 
of cardiovascular disease
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality, 
accounting for 30% of all deaths worldwide (World Health Organization 2007). In 
the United States alone, CVD accounted for more than 36% of all deaths in 2004 
or 1 of every 2.8 deaths (American Heart Association 2007). Blood pressure and 
CVD risk are directly proportional. In fact, mortality from ischemic heart disease 
and stroke doubles for every 20-mmHg increase in systolic blood pressure (SBP) 
or 10-mmHg increase in diastolic blood pressure (DBP) (Chobanian et al 2003). 
Furthermore, hypertension is often an antecedent to heart failure and myocardial 
infarction (MI). High blood pressure (140/90 mmHg) has been identiﬁ  ed in 
approximately 69% of Americans who have suffered a ﬁ  rst MI and 74% of patients 
with chronic heart failure (Rosamond et al 2008). Therefore, it is not surprising 
that successful treatment of hypertension has been shown to reduce the risk of 
stroke, coronary artery disease (CAD), and congestive heart failure, as well as 
overall cardiovascular morbidity and mortality (August 2003). However, optimal 
treatment beneﬁ  ts will not be observed unless patients adhere to their prescribed 
treatment regimens.
Adherence to prescribed medication regimens has been shown to be highest with 
once-daily dosing in several disease areas, and to decrease as the number of daily 
doses increase (Claxton et al 2001; Fonarow 2006). In fact, decreased adherence to 
a medication regimen was shown to contribute to up to 64% of rehospitalizations in 
patients with heart failure (Leventhal et al 2005; Fonarow 2006). However, tolerability Vascular Health and Risk Management 2008:4(6) 1388
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also inﬂ  uences patient adherence to a medication regimen 
(Weber et al 2006a; Carter et al 2008).
Beta-blockers have a long history in the treatment 
of hypertension and cardiac dysfunction, with more 
than 40 years of clinical use (Frishman 2007a). However, 
concerns have been raised recently from hypertension meta-
analyses regarding suboptimal outcomes with use of beta-
blockers, speciﬁ  cally atenolol, compared with outcomes for 
other antihypertensive drug classes (Lindholm et al 2005; 
Bangalore et al 2007b). Beta-blockers have also been associ-
ated with tolerability issues and concerns regarding negative 
effects on glucose and lipid metabolism. However, it should 
be noted that not all beta-blockers are identical, as differences 
in mechanism of action may translate into diverse efﬁ  cacy 
and safety proﬁ  les (Frishman 2003; Frishman 2007a).
Carvedilol is a third-generation, vasodilatory beta-
blocker that nonselectively blocks both the beta 1- and 
beta 2-adrenergic receptors and, in addition, has alpha 
1-adrenergic receptor-blocking activity. Unlike traditional 
beta-blockers (eg, atenolol, metoprolol, and proprano-
lol) that lower blood pressure by reducing cardiac output 
(Packer 1998), vasodilatory beta-blockers can lower blood 
pressure by reducing systemic vascular resistance (SVR) 
(Sundberg et al 1987). As with other beta-blockers, carvedilol 
has been shown to reduce sympathetic nervous system 
(SNS)-mediated cardiac stress and myocardial hypertrophy 
(Toda 2003). These activities likely contribute to the clini-
cal beneﬁ  ts observed in patients treated with carvedilol for 
hypertension, heart failure, and post-MI left ventricular 
dysfunction (LVD). Moreover, the regimen of twice-daily 
carvedilol has been associated with a favorable side effect 
and tolerability proﬁ  le.
In order to improve adherence to therapy and to ease 
the pill burden on patients, a controlled-release formula-
tion of carvedilol (carvedilol CR) was developed and is 
approved for use in the same indications (ie, hypertension, 
heart failure, and post-MI LVD) as immediate-release (IR) 
carvedilol. This review presents an overview of the clinical 
and pharmacologic carvedilol CR data.
Pharmacology of carvedilol
Mechanism of action
Traditional beta-blockers either selectively antagonize 
beta 1-adrenergic receptors (selective beta-blockade) or 
antagonize both beta 1- and beta 2-adrenergic receptors 
(nonselective beta-blockade). Although beta 1-selective 
agents are cardioselective, selectivity is dose dependent, and 
at high doses beta 1-selective agents may also antagonize 
beta 2-adrenergic receptors (Egan et al 2005). Traditional 
beta-blockers reduce blood pressure primarily by decreasing 
cardiac output, and systemic vascular resistance is usually 
unchanged (Messerli et al 2004). Inhibition of norepinephrine 
binding to beta-adrenergic receptors results in decreased heart 
rate and myocyte contractility (Packer 1998).
Unlike traditional beta-blockers, carvedilol blocks 
norepinephrine binding to alpha 1-adrenegric recep-
tors as well as beta 1- and beta 2-adrenegeric receptors 
(Pedersen et al 2007). Alpha 1-adrenergic receptors mediate 
vasoconstriction. Consequently, alpha 1-blockade results 
in vasodilation of the peripheral arteries, decreasing SVR 
(Packer 1998; Fonarow 2004). In addition, preclinical 
evidence suggests that carvedilol can also produce nitric 
oxide-mediated vasodilation (Kozlovski et al 2006).
Carvedilol does not possess intrinsic sympathomimetic 
activity (Toda 2003). Intrinsic sympathomimetic activity 
induces weak stimulation of the beta-adrenergic receptors that 
may dampen the positive effects of beta 1-adrenergic recep-
tor blockade (Egan et al 2005; Frishman 2007a). Of note, 
beta-blockers with intrinsic sympathomimetic activity have 
failed to demonstrate reductions in morbidity and mortality 
in patients with heart failure (Maack et al 2000).
Carvedilol has also demonstrated antioxidant effects 
possibly attributable to stimulation of endothelial nitric 
oxide production or reduced nitric oxide inactivation (Toda 
2003). Furthermore, carvedilol may protect against reactive 
oxygen species (ROS) through scavenging of free radicals, 
suppression of free radical generation, and prevention of 
ferric ion-induced oxidation (Toda 2003; Dandona et al 
2007). The ability of carvedilol to scavenge free radicals 
has been correlated with improved outcomes in patients with 
heart failure and a recent MI (Goldhammer et al 2007). In a 
study involving 39 patients with heart failure and a recent MI, 
carvedilol IR was shown to decrease oxygen free radical mea-
surements using thiobarbituric acid reactive substances assay, 
thermochemoluminescence, and conjugated dienes methodol-
ogies in 29 patients (irrespective of dosage) after 6 months of 
treatment (Goldhammer et al 2007). This decrease correlated 
with increased heart function (6-minute walk test; baseline, 
332 m and at 6 months, 397 m; p  0.05) compared with 
patients who had no evidence of reduced oxygen free radi-
cal measurements (6-minute walk test; baseline 326 m and 
at 6 months, 317 m; r = 0.83; p  0.01) (Goldhammer et al 
2007). Moreover, patients with reduced oxygen free radical 
measurements had improved clinical outcomes within 1 year 
compared with patients who had no reduction (chronic heart 
failure hospital readmissions, 10% versus 50%, respectively; Vascular Health and Risk Management 2008:4(6) 1389
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p  0.01) and death rates (3% versus 20%, respectively; 
p  0.01) (Goldhammer et al 2007).
Antioxidant activities decrease elevated oxidative stress, 
which, in turn, reduces lipid peroxidation. Reduced lipid 
peroxidation may contribute to protection from myocardial 
and brain cell ischemic death in patients with hypertension, 
heart failure, ischemic heart disease, diabetes, and renal 
dysfunction (Maggi et al 1996; Giugliano et al 1997; Moreno 
et al 1998; Nakamura et al 2002; Padi et al 2002). Anti-
oxidant activities of carvedilol may also inhibit low-density 
lipoprotein (LDL) oxidation, which could decrease accu-
mulation of oxidized LDL in vessel walls (Maggi et al 
1996). In patients with heart failure, free fatty acid levels 
become elevated (possibly from SNS hyperactivity) and the 
myocardial rate of fatty oxidation may increase; however, 
during disease progression, myocardial energy efﬁ  ciency is 
increased through a compensatory shift from the free fatty 
acid substrate to glucose (Stanley et al 2005). Preliminary 
clinical evidence suggests that pharmacologic treatments 
facilitating the compensatory metabolic switch at an earlier 
stage of disease may provide mortality beneﬁ  ts (Stanley 
et al 2005). Indeed, carvedilol has demonstrated decreased 
myocardial use of free fatty acids and either increased or 
neutral effects on myocardial glucose use in patients with 
heart failure (Wallhaus et al 2001; Podbregar et al 2002; 
Al-Hesayen et al 2005).
Carvedilol is also known to have anti-inﬂ  ammatory prop-
erties. Inﬂ  ammation has been linked to the pathogenesis of 
heart failure and atherosclerosis (Yang et al 2004; Tatli et al 
2005). In a clinical trial in patients with hypertension and 
diabetes, carvedilol IR (12.5 mg twice daily) reduced pro-
inﬂ  ammatory markers, including plasma C-reactive protein 
and monocyte chemotactic protein-1 (Dandona et al 2007). 
Furthermore, carvedilol has been shown to decrease serum 
concentrations of the inflammatory cytokines IL-6 and 
TNF-α in patients with ischemic and nonischemic dilated 
cardiomyopathy (Kurum et al 2007).
In addition, carvedilol has been shown to stimulate 
beta-arrestin signaling (Wisler et al 2007). Beta-arrestin 
is involved in the desensitization process of β-receptors in 
response to catecholamines and is implicated in G protein-
mediated cardiac remodeling in heart failure (Lefkowitz 
et al 2006; Patel et al 2008). Recent results in animal models 
suggest that beta-arrestin G protein-independent signaling 
may also occur and provide cardioprotective effects (Patel 
et al 2008). Furthermore, work is currently underway using 
beta-arrestin agonists such as carvedilol to form “super” beta-
blockers that can turn off G protein-mediated signaling of 
the beta-receptor but still maintain the beneﬁ  ts of continued 
β-arrestin-mediated signaling on cell survival systems 
(Wisler et al 2007).
Pharmacokinetics and pharmacodynamics
Carvedilol CR was developed to achieve sustained con-
centrations over a 24-hour period, allowing once-daily 
dosing. The pharmacokinetic and pharmacodynamic 
bioequivalence of carvedilol CR and IR was established 
through 2 clinical studies (Henderson et al 2006; Packer et al 
2006). In a double-blind, parallel-group, crossover study, 
122 patients with essential hypertension were randomized 
to receive either low-dose carvedilol CR (20 mg daily) or 
carvedilol IR (6.25 mg twice daily), high-dose carvedilol 
CR (80 mg once daily [initiated at 20 mg once daily and 
titrated to 40 mg and 80 mg once daily in 1-week intervals]) 
or carvedilol IR (25 mg twice daily [initiated at 6.25 mg 
twice daily and titrated to 12.5 mg and 25 mg twice daily 
in 1-week intervals]), or placebo (Henderson et al 2006). 
After 22 days of treatment, patients were crossed over to 
the equivalent alternate carvedilol formulation for 8 days of 
treatment. Patients in the placebo treatment group continued 
to receive placebo throughout the study. Pharmacokinetic 
parameters were assessed at the end of each treatment ses-
sion. The pharmacodynamic endpoint was the percentage 
change from baseline in exercise-induced heart rate. As 
carvedilol is a racemic mixture of R(+) and S(–) enantio-
mers (Nichols et al 1989), both forms were assessed in the 
pharmacokinetic analysis. The pharmacokinetic proﬁ  les of 
both enantiomers were equivalent between carvedilol CR 
and IR (Figure 1) (Henderson et al 2006). In addition, both 
formulations maintained a reduced exercise-induced heart 
rate over a 24-hour period (Henderson et al 2006).
In a separate 4-week study, patients with either mild to 
severe heart failure or with asymptomatic post-MI LVD were 
treated with the carvedilol IR (3.125, 6.25, 12.5, or 25 mg 
twice daily) for the ﬁ  rst 2 weeks and then switched to carve-
dilol CR (10, 20, 40, or 80 mg once daily) for 2 weeks (Packer 
et al 2006). Trough plasma concentration, maximum plasma 
concentration, and area under the curve was measured for 
both R(+) and S(–) enantiomers after carvedilol IR and CR 
treatment periods. The pharmacokinetics of carvedilol IR 
and CR were bioequivalent in patients with heart failure and 
post-MI with LVD. However, the median time to maximum 
observed plasma concentration for carvedilol CR lagged 
3 hours behind that of carvedilol IR, in accordance with the 
prolonged-release characteristics expected in a once-daily 
formulation. The pharmacodynamics of carvedilol CR were Vascular Health and Risk Management 2008:4(6) 1390
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Figure 1 Mean steady state concentration-time proﬁ  les for S(−) and R(+) enantiomers for carvedilol immediate-release and controlled-release. Reprinted from Henderson LS, 
Tenero DM, Baidoo CA, et al 2006. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in 
patients with hypertension. Am J Cardiol, 98:17L–26L. Copyright © 2006, with permission from Elsevier.
Abbreviations: IR, immediate release, CR, controlled release, QD, once daily.Vascular Health and Risk Management 2008:4(6) 1391
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dose proportional over the dose range tested (10 mg to 80 mg) 
(Packer et al 2006).
Notably, the bioavailability of carvedilol CR is 85% 
that of carvedilol IR (Tenero et al 2006). Carvedilol CR is 
based on carvedilol phosphate, which has a higher molecu-
lar weight than carvedilol free base and contains additional 
carvedilol free base compared with carvedilol IR to adjust 
for bioavailability. This difference contributes, in part, to 
slightly higher milligram dosage strengths of carvedilol 
CR than the “equivalent” carvedilol IR doses (Tenero 
et al 2006). A model of carvedilol pharmacokinetics that 
takes into consideration both the IR and CR formulations 
has been developed and performed robustly in leverage 
analyses (Othman et al 2007). Similar to carvedilol IR, 
the bioavailability and pharmacokinetics of carvedilol 
CR are inﬂ  uenced by food, and both formulations are 
recommended to be taken with food (Tenero et al 2006). 
However, the pharmacokinetics of carvedilol CR 40 mg 
were not affected by ethanol (38 g) intake from 2 hours 
before to 2 hours after dosing in 39 healthy volunteers 
(Henderson et al 2007).
Implications of mechanism of action
on metabolic effects and vascular health
Poor glycemic control predicts cardiovascular events; in 
particular, glycosylated hemoglobin levels linearly corre-
late with the risk of cardiovascular complications in patients 
with type 2 diabetes (Colagiuri et al 2002; Manley 2003). 
Moreover, dyslipidemia is a common comorbid condition 
in patients with hypertension (Johnson et al 2004). Men 
with a serum cholesterol level greater than 253 mg/dL have 
been shown to have a relative risk of CAD 3.8 times greater 
than men who had levels less than 181 mg/dL (Stamler 
et al 1986). Traditional, nonvasodilating beta-blockers 
have been associated with worsening of glycemic control 
and impaired lipid metabolism (Bakris et al 2006a). In 
contrast, because of its vasodilatory mechanism of action, 
which facilitates muscle uptake of glucose and increases 
the availability of lipoprotein lipase, carvedilol does not 
negatively affect glycemic control or lipid proﬁ  le compared 
with metoprolol (Messerli et al 2004). Carvedilol CR is 
currently being studied in a randomized, double-blind 
clinical trial comparing lipid effects of metoprolol succi-
nate extended release with carvedilol CR in patients with 
hypertension and either normal lipids or mild dyslipidemia 
(Bakris et al 2006b). The primary endpoints are the change 
from baseline in HDL-C and in triglycerides after 6 months 
of treatment. Several other trials have reported on glucose 
and lipid metabolism parameters using carvedilol IR and 
results have generally demonstrated improved proﬁ  les com-
pared with metoprolol (Bakris et al 2004; Basat et al 2006; 
Torp-Pedersen et al 2007).
The Glycemic Effects in Diabetes Mellitus: Carvedilol-
Metoprolol Comparison in Hypertensives (GEMINI) trial 
compared the effects of carvedilol IR (6.25 mg to 25 mg 
twice daily) with metoprolol (50 mg to 200 mg twice daily) 
on glycemic control and lipid proﬁ  le in 1235 patients with 
diabetes and hypertension (Bakris et al 2004). After 5 months 
of treatment in this randomized, double-blind, parallel-group 
trial, carvedilol IR did not increase HbA1c (0.02%; p = 0.65), 
whereas metoprolol signiﬁ  cantly increased HbA1c levels 
from baseline (0.15%; p  0.001) (Figure 2). Moreover, a 
greater number of patients withdrew because of worsening 
glycemic control in the metoprolol group (2.2%) compared 
with the carvedilol group (0.6%; p = 0.04). These data sup-
port the results of an earlier comparison study of metoprolol 
and carvedilol, which found that insulin sensitivity increased 
with carvedilol and decreased with metoprolol treatment 
(Jacob et al 1996).
Comparison of lipid parameters showed that carvedilol 
IR decreased total serum cholesterol levels to a greater 
extent than metoprolol (between-group difference, −2.9%; 
p = 0.001) in the GEMINI study (Bakris et al 2004). 
Carvedilol IR also decreased LDL cholesterol (LDL-C) com-
pared with metoprolol (between-group difference, −1.3%; 
p = 0.40). In contrast with metoprolol, carvedilol did not 
signiﬁ  cantly increase mean triglyceride levels. As kidney 
damage is a substantial concern for patients with hyperten-
sion and/or diabetes, kidney function was also measured 
in this study. Signiﬁ  cant reductions in albumin secretion 
(16% relative reduction; p = 0.003) and progression to overt 
microalbuminuria were observed with carvedilol compared 
with metoprolol (p = 0.04).
The neutral effects of carvedilol on glycemic control 
and lipid metabolism have also been established in patients 
post-MI. Fifty-nine patients post-MI were randomized to 
add either metoprolol (100 mg twice daily) or carvedilol IR 
(25 mg twice daily) to their currently prescribed regimen 
for 12 weeks (Basat et al 2006). After 12 weeks, patients 
receiving metoprolol had a signiﬁ  cantly increased homeo-
stasis model for insulin resistance (HOMA-IR), whereas 
carvedilol treatment significantly decreased HOMA-IR 
(p  0.05 compared with baseline). In addition, carvedilol 
IR signiﬁ  cantly decreased total cholesterol and LDL-C levels 
when compared with metoprolol (p = 0.043 and p = 0.021, 
respectively).Vascular Health and Risk Management 2008:4(6) 1392
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Treatment with carvedilol IR has been shown to reduce 
the incidence of diabetic events and new-onset diabetes 
among patients with heart failure. In the Carvedilol Or 
Metoprolol European Trial (COMET), 3029 patents with 
chronic heart failure were randomly assigned to treatment 
with target daily doses of carvedilol IR 50 mg or metoprolol 
tartrate 100 mg (Torp-Pedersen et al 2007). In a cohort of 
2298 patients without diabetes at trial initiation, diabetic 
events (adverse events of diabetic coma, peripheral gangrene, 
diabetic foot, decreased glucose tolerance, or hyperglycemia) 
and new-onset diabetes (clinical diagnosis, repeated high 
random glucose level, or glucose-lowering drugs) were 
assessed. Over a 5-year period, fewer diabetic events were 
reported with carvedilol IR (122 of 1151 patients; 10.6%) 
versus metoprolol (149 of 1147 patients; 13.0%; p = 0.039). 
New-onset diabetes (investigator reported) was also 
signiﬁ  cantly less prevalent in the carvedilol IR treatment 
group (119 patients; 10.3%) compared with the metoprolol 
treatment group (145 patients; 12.6%; p = 0.048)
Efﬁ  cacy of carvedilol
in cardiovascular disease
The majority of clinical data for carvedilol come from 
studies with the IR formulation. However, several studies, 
both of bioequivalence and efﬁ  cacy, have been conducted 
with carvedilol CR (Tenero et al 2006; Weber et al 2006b). 
Carvedilol CR is indicated for the treatment of hypertension, 
mild to severe heart failure, and post-MI LVD – the same 
indications as carvedilol IR. Data presented in this section 
are a mixture of carvedilol IR and CR studies.
Hypertension
The efﬁ  cacy of carvedilol CR in the treatment of hyperten-
sion was established in a double-blind, parallel-group trial 
in which patients with essential hypertension (N = 338) 
were randomized to receive carvedilol 20, 40, or 80 mg or 
placebo once daily after a 4-week washout period (Weber 
et al 2006a; Weber et al 2006b). Change from baseline 
in DBP measured by 24-hour ambulatory blood pressure 
monitoring after 6 weeks of treatment was the primary 
endpoint (Weber et al 2006a). The patient population con-
sisted of a mixture of patients, including those who were 
not receiving antihypertensive treatment, those with con-
trolled hypertension (DBP  90 mmHg) who were receiv-
ing antihypertensive treatment at baseline, and those with 
uncontrolled hypertension (DBP  90 mmHg) despite 
treatment with 2 non-beta-blocker antihypertensive agents 
at baseline. Mean sitting SBP and DBP at baseline were 
150 mmHg and 99 mmHg, respectively, indicating a popu-
lation with stage 1 hypertension (Chobanian et al 2003). 
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Placebo-adjusted change from baseline in 24-hour DBP 
was −4.03, −7.56, and −9.19 mmHg, respectively, with 
carvedilol CR 20, 40, and 80 mg (p  0.001) (Weber et al 
2006a). Signiﬁ  cant reductions in placebo-adjusted 24-hour 
SBP were also observed (−6.12, −9.43, and −11.85 mmHg, 
respectively) (Weber et al 2006b). Carvedilol CR treatment 
resulted in signiﬁ  cant, dose-dependent reductions in peak 
and trough blood pressure measurements (Figure 3). Blood 
pressure control, deﬁ  ned as DBP  90 mmHg, was achieved 
by 45% to 53% of patients treated with carvedilol compared 
with only 15% of patients who received placebo. Pulse pres-
sure was assessed via an ad hoc analysis and was signiﬁ  cantly 
reduced with carvedilol versus placebo (p  0.05).
These data build on the established safety and efﬁ  cacy of 
carvedilol IR in the treatment of hypertension demonstrated 
in several US and international placebo-controlled trials. In 
patients with hypertension, carvedilol IR has been shown 
to reduce blood pressure and exercise and resting heart 
rates (Pedersen et al 2007). Blood pressure reductions are 
likely linked to reductions in SVR in addition to the other 
BP-lowering properties of all beta-blockers, which have been 
demonstrated in healthy volunteers treated with carvedilol IR 
(Sundberg et al 1987).
The antihypertensive efﬁ  cacy of carvedilol has been 
reported in patients with hypertension and comorbid 
conditions, such as diabetes, which make hypertension more 
difﬁ  cult to treat (Bakris et al 2004; Wright et al 2007). In the 
previously described GEMINI trial, carvedilol IR lowered 
SBP by 18.1 mmHg and DBP by 9.9 mmHg, which was 
consistent with the 16.9 mmHg and 9.5 mmHg decreases 
in SBP and DBP, respectively, observed with metoprolol 
(Bakris et al 2004). At the end of the beta-blocker titration 
period, 37% and 36% of patients treated with carvedilol IR 
and metoprolol, respectively, achieved blood pressure goals 
(130/80 mmHg for patients with diabetes) (Wright et al 
2007). It should be noted that patients enrolled in this study 
were already receiving a stable regimen of antihypertensive 
therapy with an angiotensin-converting enzyme (ACE) 
inhibitor or an angiotensin-receptor blocker.
Carvedilol CR has demonstrated efﬁ  cacy in the treat-
ment of hypertension providing blood pressure control in 
up to 53% of the clinical patient population, which included 
patients with uncontrolled hypertension already receiving 
other classes of antihypertensive agents (Weber et al 2006a). 
Additionally, based on the results of trials conducted with 
carvedilol IR, carvedilol CR may provide an equivalent 
extent of efﬁ  cacy in more difﬁ  cult to treat patients such as 
those patients with hypertension and diabetes.
Heart failure
Along the cardiovascular continuum, heart failure is a 
natural progression of uncontrolled hypertension. A recently 
completed trial in patients with heart failure compared 
the effects of carvedilol CR with those of carvedilol IR. 
Figure 3 Controlled-release carvedilol in hypertension.  Adapted from Weber MA, Sica DA, Tarka EA, et al Controlled-release carvedilol in the treatment of essential hypertension. 
Am J Cardiol, 98:32L–38L. Copyright © 2006, with permission from Elsevier.
Abbreviations: CR, controlled release, DBP, diastolic blood pressure, SBP, systolic blood pressure.
Note: Data are change from baseline in model-adjusted peak (3 to 7 hours) diastolic blood pressure and systolic blood pressure measured by ambulatory blood pressure 
monitoring. *p  0.05, †p  0.001, ‡p  0.0001, based on pair-wise comparison of change from baseline with placebo.
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Coreg: A Multicenter, Randomized, Double-Blind, 
Double-Dummy, Parallel-Group Study to Compare Effects 
of Coreg CR and Coreg IR on Ejection Fraction in Subjects 
With Stable Heart Failure (COMPARE) trial randomized 
patients with mild to severe heart failure and a left ventricular 
ejection fraction of 40% (N = 253) to either carvedilol CR 
(from 10 to 80 mg once daily) or carvedilol IR (from 3.125 to 
25 mg twice daily) for up to 8 months (Greenberg et al 2006). 
The primary efﬁ  cacy endpoint was the change from baseline 
in left ventricular end-systolic volume index at 6 months. 
Secondary endpoints included change from baseline in left 
ventricular remodeling and serum B-type natriuretic peptide, 
hospitalization for heart failure and all other causes, death 
from all causes, compliance, and safety and tolerability of 
carvedilol CR. Full results are not yet published.
The beneﬁ  cial effects of carvedilol IR have been dem-
onstrated along the spectrum of severity from mild to severe 
heart failure (Frishman 1998). The Australia/New Zealand 
(ANZ) double-blind trial randomized 415 patients with 
chronic, stable, mild heart failure to receive either carve-
dilol IR (from 3.125 mg to 25 mg, as tolerated) or placebo 
twice daily for 12 months (Australia/New Zealand Heart 
Failure Research Collaborative Group 1997). Carvedilol IR 
increased left ventricular ejection fraction from baseline 
by 5.1% at 12 months and decreased left-ventricular and 
end-systolic dimensions by 1.7 mm and 3.2 mm, respec-
tively, compared with placebo. After a mean follow-up of 
19 months, carvedilol IR decreased the combined risk of 
death or hospitalization in patients with heart failure risk by 
26% versus placebo.
The US Carvedilol Heart Failure Study Group enrolled 
1094 patients with mild to severe heart failure in a double-
blind, stratiﬁ  ed program, assigning patients to 1 of 4 treat-
ment protocols on the basis of their exercise capacity (Packer 
et al 1996). The mortality and hospitalization data from these 
4 trials were analyzed together and considered together by 
the Data and Safety Monitoring Board for the trial. Patients 
were randomized to receive carvedilol IR (from 6.25 to 
50 mg, if tolerated) or placebo twice daily and were followed 
for 6 months (12 months for the mild heart failure group). 
Compared with placebo, carvedilol IR signiﬁ  cantly reduced 
mortality rates (3.2% versus 7.8%; p  0.001), risk of hos-
pitalization for cardiovascular causes (14.1% versus 19.6%; 
p = 0.036), and the combined endpoint of hospitalization or 
death (15.8% versus 24.6%; p  0.001). The program was 
stopped early based on the signiﬁ  cant improvements in sur-
vival with carvedilol IR compared with placebo. This ﬁ  nding 
is notable as the patients were only followed for an average 
of 6.5 months, which is a treatment period usually considered 
too short in duration to observe an effect on mortality and 
morbidity rates.
The Carvedilol Prospective Randomized Cumulative 
Survival (COPERNICUS) study randomized 2289 patients 
with symptoms of heart failure at rest or on minimal exertion 
with a left ventricular ejection fraction of 25% (ie, severe 
heart failure) to receive either placebo or carvedilol IR, 
(from 3.125 mg to 25 mg, as tolerated) (Packer et al 2002). 
Treatment with carvedilol IR resulted in a 27% reduction 
of the combined endpoint of death or hospitalization for a 
cardiovascular reason (p  0.0001 versus placebo), as well 
as a 31% reduction in the combined endpoint of death or 
hospitalization for heart failure (p  0.001 versus placebo). 
Carvedilol IR treatment also signiﬁ  cantly reduced the fre-
quency of serious adverse events, including worsening heart 
failure, sudden death, cardiogenic shock, and ventricular 
tachycardia (p = 0.002 versus placebo).
Additionally, over a mean duration of 58 months in the 
COMET study, signiﬁ  cantly fewer deaths occurred in the 
carvedilol group (512 of 1511 patients; 34%) compared with 
the metoprolol group (600 of 1518 patients; 40%; p = 0.0017) 
(Figure 4) (Poole-Wilson et al 2003). Cardiovascular death 
was less prevalent in the carvedilol group than in the meto-
prolol group (438 versus 534 patients; p = 0.0004), as were 
sudden death, circulatory failure, and stroke (Poole-Wilson 
et al 2003; Torp-Pedersen et al 2005). Results for the com-
bined endpoint of all-cause mortality or all-cause admissions 
were similar in both groups (74% and 76% of patients for 
carvedilol IR and metoprolol, respectively). It should be 
noted that metoprolol tartrate at 50 mg twice daily has not 
been shown in clinical trials to provide a mortality beneﬁ  t. 
However, of note in the metoprolol succinate heart failure 
trial (MERIT-HF), the mean daily dose was 159 mg daily, 
which is equivalent to 106 mg daily of metoprolol tartrate 
(Poole-Wilson et al 2003).
Another long-term study that compared carvedilol 
IR (49 mg daily) with metoprolol tartrate (124 mg daily) 
in patients with chronic heart failure (N = 150) dem-
onstrated a greater decrease in exercise heart rate with 
carvedilol than with metoprolol after 13 to 15 months of 
treatment (p = 0.006) (Metra et al 2000). In contrast, a 
recent trial comparing carvedilol IR (32 mg daily) and 
metoprolol succinate (96 mg daily) in a similar patient 
population (N = 37) observed a significant increase 
in exercise heart rate with carvedilol versus meto-
prolol (135 ± 4 versus 117 ± 6 beats/minute, respec-
tively; p = 0.02), although peak exercise norepinephrine Vascular Health and Risk Management 2008:4(6) 1395
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levels were similar (2736 ± 320 versus 2403 ± 372 pg/mL, 
respectively) (Vittorio et al 2008). These findings are of 
note because attenuation of exercise-induced heart rate 
is used as a surrogate for the extent of beta 1-adrenergic 
blockade and possibly to evaluate dosing equivalency. 
Many reasons may contribute to the results of these trials, 
including nonequivalent doses or different formulations 
or durations of treatment.
Post-MI LVD
Carvedilol is currently the only beta-blocker approved for 
use in patients with post-MI LVD. The only clinical data 
available in this patient population is with carvedilol IR. The 
Carvedilol Post-Infarct Survival Control in LV Dysfunction 
(CAPRICORN) study investigated the beneﬁ  ts of a beta-
blocker (carvedilol IR) in patients with post-MI LVD who 
were receiving standard therapy. In this double-blind trial, 
1959 patients who had experienced an MI and had a left ven-
tricular ejection fraction 40% were randomized to receive 
either carvedilol IR (from 6.25 mg up to 25 mg as tolerated) 
or placebo twice daily (Dargie 2001). The mean follow-up 
duration was 1.3 years, and 74% of patients achieved the 
maximum dose of carvedilol IR (25 mg twice daily). In this 
study, carvedilol IR decreased all-cause mortality by 23% 
versus placebo (Figure 5). However, there was no signiﬁ  cant 
difference between groups in the composite endpoint of 
all-cause mortality or cardiovascular hospital admission. Data 
from CAPRICORN showed that carvedilol IR has antiar-
rhythmic effects post-MI (McMurray et al 2005). Moreover, 
a substudy from CAPRICORN reported positive effects 
of carvedilol IR on ventricular remodeling (Doughty et al 
2004). The authors speculate that the inﬂ  uence on ventricular 
remodeling may be a substantial contributing factor to the 
clinical efﬁ  cacy observed in patients with post-MI LVD. 
More recently, Fonarow and colleagues assessed the 30-day 
outcomes from CAPRICORN. Reductions with carvedilol IR 
versus placebo were observed in mortality, fatal or nonfatal 
MI; the composite endpoint of death, nonfatal MI, or cardiac 
arrest; and the composite endpoint of all-cause mortality or 
nonfatal MI (Fonarow et al 2007).
Based on the CAPRICORN data, the number needed 
to treat to prevent 1 death for 1 year was 43 (Otterstad 
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et al 2002). This compares favorably with data from the 
atenolol Beta-Blocker Heart Attack Trial (BHAT) showing 
that 80 patients would need treatment for 1 year to prevent 
1 death (Otterstad et al 2002). In contrast, the Norwegian 
Timolol Trial reported that 25 patients needed treatment for 
1 year to prevent 1 death (Otterstad et al 2002).
Safety and tolerability 
of carvedilol CR
The clinical utility of traditional beta-blockers has been 
limited by concerns regarding negative effects on glucose and 
lipid metabolism (Bakris et al 2006a; Bangalore et al 2007b) 
and a high incidence of side effects, including fatigue, erectile 
dysfunction, and weight gain (Bangalore et al 2007b). Unlike 
traditional beta-blockers, the alpha 1-blocking vasodilatory 
activity with carvedilol does not interfere with glucose and 
lipid metabolism (discussed previously) and has a positive 
inﬂ  uence on its tolerability proﬁ  le.
Carvedilol CR is generally well tolerated across its 
therapeutic indications (Henderson et al 2006; Packer 
et al 2006; Weber et al 2006a). Adverse events reported 
in clinical trials were consistent with the mechanism of 
action of carvedilol and the health status of the patient 
population under evaluation. In the bioequivalence study 
in patients with hypertension (N = 122), the proportion of 
patients who experienced an adverse event was lower with 
carvedilol CR compared with carvedilol IR (Henderson 
et al 2006). Moreover, headache, orthostatic hypoten-
sion, diarrhea, and dizziness occurred more frequently 
with carvedilol IR than with carvedilol CR (Table 1) 
(Henderson et al 2006). It must be acknowledged, how-
ever, that this was a small study (122 patients) of short 
duration (approximately 5 weeks). The adverse event pro-
ﬁ  le was comparable between carvedilol IR and carvedilol 
CR among patients with heart failure or post-MI enrolled 
in a pharmacokinetics study, with no notable increase in 
events when patients were switched from carvedilol IR 
to CR (Packer et al 2006). In the carvedilol CR hyperten-
sion efﬁ  cacy study, the occurrences of fatigue, dizziness, 
and headache were comparable between the combined 
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carvedilol dose groups and the placebo group (Weber 
et al 2006a).
Potential for improving patient 
adherence to therapy
Reducing pill burden
Use of multiple concomitant medications in the treatment 
of hypertension, heart failure, and MI contributes to the 
polypharmacy that is common among patients receiving 
carvedilol. Combinations of diuretics, ACE inhibitors, 
digitalis, glycosides, and beta-blockers are common in 
the treatment regimen for patients with heart failure. After 
an MI, guidelines recommend treatment with multiple 
evidence-based medications, including aspirin, clopidogrel, 
a statin, an ACE inhibitor, and a beta-blocker. In the ﬁ  eld of 
hypertension, few patients achieve adequate blood pressure 
control on monotherapy (Bangalore et al 2007a). In fact, in 
ALLHAT, a mean of 2 drugs was required to reach blood 
pressure targets (Cushman et al 2002). Couple these ﬁ  nd-
ings with the treatment regimens for common comorbidities 
(eg, diabetes, coronary artery disease), and the pill burden 
can become quite substantial.
Both the number of pills taken daily and frequency of 
dosing affect patient adherence to prescribed therapies, and 
adherence, in turn, inﬂ  uences clinical outcomes (Claxton 
et al 2001). In patients with hypertension, lack of adherence 
has been shown to reduce treatment beneﬁ  t and increase the 
risk of poor treatment outcome (Frishman 2007b). Among 
patients post-MI, lack of adherence to statins, calcium 
channel blockers, and beta-blockers signiﬁ  cantly increased 
mortality risk (p = 0.001) (Rasmussen et al 2007).
One method for reducing pill burden is to design drugs 
that can be dosed less frequently. One such example is 
carvedilol CR. Once-daily dosing has been shown to improve 
adherence (Frishman 2007b). Data compiled from 76 stud-
ies covering a range of therapeutic areas demonstrated that 
once-daily dosing is associated with the highest adherence 
rate among various dosing regimens (Claxton et al 2001).The 
levels of adherence declined as the number of daily doses 
increased (79% for once daily, 69% for twice daily, 65% 
for 3 times daily, and 51% for 4 times daily). Moreover, the 
adherence beneﬁ  t of once-daily dosing has been speciﬁ  cally 
observed with a beta-blocker (metoprolol) used for the treat-
ment of hypertension (Baird et al 1984).
The Compliance and Quality of Life Study Comparing 
Once-Daily Controlled-Release Carvedilol CR and Twice-
Daily Immediate-Release Carvedilol IR in Patients with 
Heart Failure (CASPER) trial was based on the assump-
tions that adherence to the medication regimen would be 
Table 1 Treatment-related adverse events with IR and CR carvedilola
Regimen
Carvedilol IRb BID Carvedilol CRb QD
Variable 6.25 mg 12.5 mg 25 mg 20 mg 40 mg 80 mg Placeboc
Patients exposed (n) 65 26 50 67 26 51 63
Patients with adverse events, n (%) 18 (27.7) 5 (19.2) 14 (28.0) 17 (25.4) 1 (3.8) 7 (13.7) 16 (25.4)
Adverse event, n (%)
  Headache 11 (16.9) 3 (11.5) 10 (20) 6 (9.0) 1 (3.8) 5 (9.8) 7 (11.1)
  Orthostatic hypotension 3 (4.6) 2 (7.7) 2 (4.0) 3 (4.5) 0 (0) 2 (3.9) 5 (7.9)
  Dizziness 3 (4.6) 2 (7.7) 3 (6.0) 1 (1.5) 0 (0) 0 (0) 4 (6.3)
  Fatigue 0 (0) 0 (0) 0 (0) 1 (1.5) 0 (0) 0 (0) 2 (3.2)
  Somnolence 0 (0) 0 (0) 1 (2.0) 2 (3.0) 0 (0) 0 (0) 0 (0)
  Asthenia 2 (3.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
  Dyspepsia 1 (1.5) 0 (0) 0 (0) 1 (1.5) 0 (0) 0 (0) 0 (0)
  Edema, peripheral 1 (1.5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.0) 0 (0)
  Hypotension 1 (1.5) 0 (0) 0 (0) 1 (1.5) 0 (0) 0 (0) 0 (0)
aOnly the most commonly reported adverse events (considered by the investigator to be related to study medication) are listed.
bAdverse events attributed to any dose of carvedilol IR or carvedilol CR include events that were reported by patients in any treatment group who were receiving the designated 
regimen (sessions 1–4), adverse events that occurred in the downtitration period are not included (session 5).
cPlacebo group included the downtitration period (session 5) for the 2 low-dose groups that previously received carvedilol in sessions 1–4.
Abbreviations: CR, controlled release, IR, immediate release, BID, twice daily, QD, once daily.
Reprinted from Henderson LS, Tenero DM, Baidoo CA, et al Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release 
carvedilol at steady state in patients with hypertension, Am J Cardiol, 98:17L–26L. Copyright © 2006, with permission from Elsevier.Vascular Health and Risk Management 2008:4(6) 1398
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75% with twice-daily medication and 90% with once-daily 
medication (Hauptman et al 2006). Patients with mild to 
severe heart failure and a left ventricular ejection fraction 
of 40% or less were randomized to either a double-blind 
arm (morning carvedilol CR plus an evening placebo versus 
morning and evening carvedilol IR) or to an open-label arm 
(carvedilol CR). However, preliminary results demonstrated 
no difference in patient adherence between once-daily and 
twice-daily regimens (88% versus 89%) (Udelson et al 2007; 
Carter et al 2008). These results may be explained, in part, 
by the consideration that patient adherence may be higher 
in clinical trials than in the community setting. Indeed, the 
carvedilol IR recipients in this trial had a higher than antici-
pated compliance rate.
Another option for reducing pill burden is to reduce 
the number of individual pills through use of a ﬁ  xed-dose 
combination (FDC). Fixed-dose combinations have become 
increasingly common in the ﬁ  eld of hypertension because of 
the frequent need for multiple concomitant antihypertensives 
to control blood pressure. Fixed-dose combinations may also 
work synergistically, resulting in a lower total dose of each 
individual drug (Rao et al 1998). The ability to reduce drug 
doses can also reduce the risk of side effects. Use of an FDC 
may also have positive effects on patient adherence. In a 
study comparing adherence between patients treated with an 
FDC (n = 11,925) and patients treated with a free-drug regi-
men (n = 8317), those receiving an FDC had a signiﬁ  cantly 
decreased risk of nonadherence (p  0.0001) (Bangalore 
et al 2007a).
An FDC consisting of carvedilol and the ACE inhibi-
tor lisinopril is currently in development. The Coreg and 
Lisinopril Combination Therapy in Hypertensive Subjects 
(COSMOS) trial is assessing the efﬁ  cacy and safety of a 
carvedilol/lisinopril FDC (ClinicalTrials.gov Identifier: 
NCT00347360). COSMOS is a randomized, double-blind, 
double-dummy, parallel-group trial employing a 4 × 4 
factorial design that will evaluate carvedilol (20, 40, or 
80 mg daily) alone, lisinopril (10, 20, or 40 mg daily) alone, 
and all permutations of the combined drugs in patients with 
hypertension.
Quality of life and patient satisfaction
Quality of life is more difﬁ  cult to assess than concrete 
measures such as blood pressure or mortality. If improved 
tolerability and reduced risk for side effects were consid-
ered, one would anticipate an improvement in this category 
with carvedilol as appraised relative to traditional beta-
blockers.
Some clinical trials have revealed improvements in 
patient-reported quality-of-life assessments. The effects of 
carvedilol IR on patient global assessment were reported 
in patients with heart failure (Packer et al 2002). In a 
study of 2289 patients with heart failure, patients receiv-
ing treatment with carvedilol were more likely to show 
moderate or marked improvement and less likely to show 
moderate or marked worsening versus placebo. In the 
previously described COMET study, a patient-completed, 
self-assessment scoring system that was evaluated every 
4 months of treatment demonstrated a significantly 
improved self-score for patients treated with carvedilol 
(p  0.0068) (Cleland et al 2006).
A prespecified secondary analysis of the GEMINI 
study used the Diabetes Symptom Checklist to record 
patient-reported occurrences of diabetes-related symptoms 
in 8 domains, namely psychology (fatigue), psychology 
(cognitive), neuropathy (pain), neuropathy (sensory), 
cardiology, ophthalmology, hyperglycemia, and hypogly-
cemia (McGill et al 2007). After 5 months of treatment, 
the results signiﬁ  cantly favored carvedilol over metoprolol 
tartrate in overall maintenance score (p = 0.02), hypogly-
cemia symptoms (p = 0.02), and hyperglycemia symptoms 
(p = 0.005).
Conclusions
The varied mechanisms of action of carvedilol allow it to 
be an effective treatment of hypertension, heart failure, and 
post-MI LVD, with less of the metabolic and tolerability 
concerns associated with traditional beta-blockers. The 
key difference from the majority of beta-blockers appears 
to be vasodilation mediated by alpha 1-adrenergic recep-
tor blockade, which decreases total peripheral resistance 
(Pedersen et al 2007). Furthermore, carvedilol’s antioxidant 
and anti-inﬂ  ammatory effects may provide additional car-
dioprotective effects beyond that of traditional beta-blockers 
(Dandona et al 2007). Carvedilol has a long history and a 
proven track record in the treatment of hypertension and 
cardiac dysfunction. The once-daily formulation of carve-
dilol provides a more convenient option and may confer 
an adherence beneﬁ  t over the twice-daily formulation in 
conditions traditionally prone to noncompliance such as 
hypertension and post-MI LVD.
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